Company intelligence / Profile preview

OrPro Therapeutics, Inc.

San Diego, California, United Statesorprotherapeutics.com ↗

Ownership: Private
Employees: ~10
Development stage: Preclinical

Overview

OrPro is developing ORP100S, a novel biologic therapy based on thioredoxin derivatives. The company has received funding from the US Department of Defense to advance ORP100S development for COVID-19 and influenza treatment. The drug has shown promise in lowering inflammation in acute lung injury and preventing viral pneumonia in animal models.

Therapeutic areas: GastroenterologyOphthalmologyPulmonologyInfectious Diseases
Modalities: Biologics (non-systemic biologic drug platform)
Industry: Biotech

Drug pipeline

2 assets

ORP-100

Preclinical

1 more asset in the full pipeline.

Request access →

Partnerships

National Jewish HealthUniversity of North Carolina at Chapel HillUniversity of Alabama-Birmingham

Beyond the preview

Go deeper on OrPro Therapeutics, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OrPro Therapeutics, Inc..

Explore the full profile